What are Alnylam Pharmaceuticals's profit margins?

Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.

Where do Alnylam Pharmaceuticals's ratios come from?

Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Alnylam Pharmaceuticals ALNY Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Gross margin	81%-0.8pp	81.8%-2.3pp	84%+0.2pp	83.9%-2.4pp	86.3%-0.1pp
Operating margin	17.5%+4.0pp	13.5%+5.3pp	8.2%+15.6pp	-7.3%-2.4pp	-4.9%+3.0pp
Net margin	11.7%+4.2pp	7.5%+4.9pp	2.6%+13.9pp	-11.4%-1.6pp	-9.8%+2.6pp
EBITDA margin	18.8%+3.8pp	15%+5.0pp	10%+15.0pp	-5%-2.6pp	-2.5%+2.9pp
Free cash flow margin	15%+2.5pp	12.5%+5.6pp	6.9%+9.0pp	-2.1%+1.2pp	-3.3%-1.4pp
Returns
Return on equity	66.9%+2.0pp	65%+2.8pp	62.2%—	——	——
Return on assets	10.8%+4.7pp	6%+4.2pp	1.8%+8.4pp	-6.5%-0.8pp	-5.7%+1.2pp
Efficiency
Asset turnover	0.9×+0.1×	0.8×+0.1×	0.7×+0.1×	0.6×0.0×	0.6×0.0×
Inventory turnover	10.9×+2.5×	8.4×+1.6×	6.8×+1.7×	5.1×+1.1×	4×+0.4×
Liquidity
Current ratio	3.1×+0.4×	2.8×+0.2×	2.5×-0.3×	2.8×-0.2×	3×+0.3×
Quick ratio	3.1×+0.4×	2.7×+0.2×	2.5×-0.3×	2.7×-0.2×	3×+0.3×
Cash ratio	1.3×+0.1×	1.1×+0.2×	1×+0.1×	0.9×-0.1×	1×+0.1×
Leverage
Debt-to-equity	0.2×-0.1×	0.3×-0.8×	1.1×+0.1×	1.1×+0.4×	0.6×-3.4×
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Net debt / EBITDA	-1.8×+0.7×	-2.5×+1.3×	-3.8×—	——	——
Interest coverage	3.4×+1.0×	2.4×+1.0×	1.5×+2.5×	-1×-0.3×	-0.7×+0.5×
Per Share
Book value per share	$7.78+32.8%	$5.86+244%	$1.70-11.2%	$1.92-41.6%	$3.29+525%
Valuation
Market capitalization	$43.88B-16.5%	$52.54B-12.1%	$59.77B+41.1%	$42.38B+21.3%	$34.95B+15.1%
Enterprise value	$42.43B-17.0%	$51.15B-12.6%	$58.55B+41.0%	$41.53B+21.4%	$34.2B+15.3%
Price / earnings	87.4×-102×	188.9×-533×	721.9×—	——	——
Price / sales	10.2×-3.9×	14.1×-4.5×	18.6×+1.4×	17.2×+2.3×	14.9×+1.4×
Price / book	40.8×-25.8×	66.6×-189×	255.6×+86.4×	169.1×+87.1×	82×-370×
EV / EBITDA	52.6×-39.2×	91.8×-90.6×	182.4×—	——	——
EV / sales	9.9×-3.9×	13.8×-4.5×	18.2×+1.4×	16.9×+2.3×	14.6×+1.4×
Free cash flow yield	1.5%+0.6pp	0.9%+0.5pp	0.4%+0.5pp	-0.1%+0.1pp	-0.2%-0.1pp
Earnings yield	1.1%+0.6pp	0.5%+0.4pp	0.1%+0.8pp	-0.7%0.0pp	-0.7%+0.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Alnylam Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Alnylam Pharmaceuticals's profit margins?: Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
Where do Alnylam Pharmaceuticals's ratios come from?: Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.